<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>organoid technology &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/organoid-technology/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 06 Jan 2026 07:10:23 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>organoid technology &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Organoids Forecast Chemotherapy, PARP Inhibitor Outcomes in Ovarian Cancer</title>
		<link>https://bioengineer.org/organoids-forecast-chemotherapy-parp-inhibitor-outcomes-in-ovarian-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 06 Jan 2026 07:09:58 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[organoid technology]]></category>
		<category><![CDATA[Ovarian cancer]]></category>
		<category><![CDATA[PARP inhibitors]]></category>
		<category><![CDATA[personalized medicine]]></category>
		<category><![CDATA[Treatment Response Prediction]]></category>
		<guid isPermaLink="false">https://bioengineer.org/organoids-forecast-chemotherapy-parp-inhibitor-outcomes-in-ovarian-cancer/</guid>

					<description><![CDATA[In a groundbreaking study that could reshape the treatment landscape for advanced ovarian cancer, researchers have successfully utilized patient-derived organoids as a predictive tool for chemotherapy responses and the efficacy of PARP inhibitors. This innovative approach has the potential to personalize treatment regimens, ensuring that patients receive the most effective therapies tailored specifically to their [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">314049</post-id>	</item>
		<item>
		<title>Chinese Scientists Create Assembloid Model to Unravel Adenomyosis Pathogenesis</title>
		<link>https://bioengineer.org/chinese-scientists-create-assembloid-model-to-unravel-adenomyosis-pathogenesis/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 09 Sep 2025 16:32:06 +0000</pubDate>
				<category><![CDATA[Biology]]></category>
		<category><![CDATA[adenomyosis pathogenesis]]></category>
		<category><![CDATA[assembloid model]]></category>
		<category><![CDATA[BMP/WNT signaling]]></category>
		<category><![CDATA[organoid technology]]></category>
		<category><![CDATA[single-cell transcriptomics]]></category>
		<guid isPermaLink="false">https://bioengineer.org/chinese-scientists-create-assembloid-model-to-unravel-adenomyosis-pathogenesis/</guid>

					<description><![CDATA[Adenomyosis is a complex and often debilitating gynecological condition that affects millions of women worldwide, yet remains poorly understood in terms of its pathogenesis and therapeutic interventions. Characterized by the invasion of endometrial tissue into the myometrium—the muscular layer of the uterus—adenomyosis leads to uterine enlargement, irregular menstruation, secondary dysmenorrhea, and impaired fertility. Despite its [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">268019</post-id>	</item>
	</channel>
</rss>
